Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-05

Clinical Trial Update: Nicotinic Receptors and Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nicotinic receptor targets in schizophrenia. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: VA Office of Research and Development | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2016-02-05